Secondary prevention of ischaemic cardiac events
- PMID: 21875445
- PMCID: PMC3217663
Secondary prevention of ischaemic cardiac events
Abstract
Introduction: Coronary artery disease is the leading cause of mortality in resource-rich countries, and is becoming a major cause of morbidity and mortality in resource-poor countries. Secondary prevention in this context is long-term treatment to prevent recurrent cardiac morbidity and mortality in people who have had either a prior acute myocardial infarction (MI) or acute coronary syndrome, or who are at high risk due to severe coronary artery stenoses or prior coronary surgical procedures. Secondary prevention in people with an acute MI or acute coronary syndrome within the past 6 months is not included.
Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antithrombotic treatment; other drug treatments; cholesterol reduction; blood pressure reduction; non-drug treatments; and revascularisation procedures? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Results: We found 137 systematic reviews or RCTs that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
Conclusions: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: advice to eat less fat, advice to eat more fibre, advice to increase consumption of fish oils, amiodarone, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, angiotensin II receptor blockers plus ACE inhibitors, antioxidant vitamin combinations, antiplatelet agents, aspirin, beta-blockers, beta-carotene, blood pressure reduction, calcium channel blockers, cardiac rehabilitation including exercise, class I antiarrhythmic agents, coronary artery bypass grafting (CABG), fibrates, hormone replacement therapy (HRT), Mediterranean diet, multivitamins, non-specific cholesterol reduction, oral anticoagulants, oral glycoprotein IIb/IIIa receptor inhibitors, percutaneous coronary intervention (PCI), psychosocial treatment, smoking cessation, statins, vitamin C, and vitamin E.
Similar articles
-
Heart failure.BMJ Clin Evid. 2011 Aug 30;2011:0204. BMJ Clin Evid. 2011. PMID: 21878135 Free PMC article.
-
Myocardial infarction (ST-elevation).BMJ Clin Evid. 2011 Jan 7;2011:0202. BMJ Clin Evid. 2011. PMID: 21477402 Free PMC article.
-
Myocardial infarction (ST-elevation).BMJ Clin Evid. 2009 Jan 9;2009:0202. BMJ Clin Evid. 2009. PMID: 19445779 Free PMC article.
-
Exercise-based cardiac rehabilitation for coronary heart disease.Cochrane Database Syst Rev. 2021 Nov 6;11(11):CD001800. doi: 10.1002/14651858.CD001800.pub4. Cochrane Database Syst Rev. 2021. PMID: 34741536 Free PMC article.
-
Heart failure.BMJ Clin Evid. 2010 Feb 25;2010:0204. BMJ Clin Evid. 2010. PMID: 21718583 Free PMC article.
Cited by
-
Simultaneous Delivery of Wharton's Jelly Mesenchymal Stem Cells and Insulin-Like Growth Factor-1 in Acute Myocardial Infarction.Iran J Pharm Res. 2018 Spring;17(2):426-441. Iran J Pharm Res. 2018. PMID: 29881402 Free PMC article.
-
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.Cochrane Database Syst Rev. 2016 Dec 24;12(12):CD007888. doi: 10.1002/14651858.CD007888.pub3. Cochrane Database Syst Rev. 2016. PMID: 28012165 Free PMC article.
References
-
- American Heart Association. Heart disease and stroke statistics – 2004 update. Dallas, Texas: American Heart Association, 2004.
-
- Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162:2197–2202. - PubMed
-
- Serebruany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004;75:40–47. - PubMed
-
- He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke. A meta-analysis of randomised controlled trials. JAMA 1998;280:1930–1935. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous